Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 6:72:102606.
doi: 10.1016/j.eclinm.2024.102606. eCollection 2024 Jun.

Development and validation of a novel Barrett's oesophagus patient reported outcome measure (B-PROM)

Elizabeth Ratcliffe  1   2 , James Britton  2   3 , Sharon Baines  3 , Neeraj Prasad  1 , Richard Keld  1 , Mark Murgatroyd  4 , Miguel Montenegro  5 , Elaine Viloria  5 , John McLaughlin  2   3 , Shaheen Hamdy  2   3 , Yeng Ang  2   3 ; B-PROM Delphi contributors; Methodological advice collaborators
Collaborators, Affiliations

Development and validation of a novel Barrett's oesophagus patient reported outcome measure (B-PROM)

Elizabeth Ratcliffe et al. EClinicalMedicine. .

Abstract

Background: Patients with Barrett's oesophagus (BO) carry significant cancer worry, burden of symptoms, and lack disease-specific knowledge. Currently there is no validated BO patient reported outcome measure (PROM) to measure these factors for use in clinical practice and research, hence the aim of this study was to devise a novel, validated BO-specific tool, B-PROM.

Methods: Literature review, quantitative and qualitative research informed the initial item generation. The item bank was refined through a modified Delphi process between May and August 2021. The PROM was then tested through cognitive interviews and validated via multicentre testing between September 2021 and February 2023 with the aim to create a succinct tool which addresses the key important factors to BO patients and has strong psychometric properties.

Findings: B-PROM covers key themes of disease-specific knowledge, trust in clinicians, burden of symptoms, cancer worry and burden of surveillance. Validation results from 387 participants (response rate 40.8%) showed 93.3% of participants completed >95% of B-PROM. All individual items scored a completion rate of >95%. Mean completion time was 5 mins 34s for a sample group. Nineteen items showed a ceiling effect, 3 items showed a floor effect. Internal consistency overall demonstrated a Cronbach Alpha of 0.846, while predetermined subsections showed Cronbach alphas of 0.335, 0.718, 0.736, and 0.896. Inter-item analysis found 2 pairs of items with strong correlation, with only 6 items correlating weakly. Item-total correlation showed 19 items correlated well. Exploratory Factor analysis (EFA) with principal component analysis produced 5 components with Eigenvalues >1 of which 4/5 had satisfactory Cronbach alphas. Test-retest reliability showed no significant differences across single and average measures (p ≤ 0.001).

Interpretation: B-PROM is the first BO-specific PROM to be systematically evaluated. Validation findings show strong internal consistency, short completion time, low missingness and excellent test-retest reliability.

Funding: Medtronic Limited ISR-2016-1077.

Keywords: Barrett's oesophagus; Cancer; Endoscopy; Health related quality of life; Patient reported outcome measures.

PubMed Disclaimer

Conflict of interest statement

YA has received funding from cancer research UK and Medtronic Ltd. ER has received research funding from Medtronic UK and speaker honoraria from Janssen and Takeda. SH has NIHR funding for other research studies, is on the board of ESSD and holds shares in the company Phagenesis Ltd.

Figures

Fig. 1
Fig. 1
A conceptual model demonstrating the key areas of Barrett's oesophagus impact on patients from quantitative and qualitative work looking at health related quality of life in Barrett's oesophagus patients.
See this image and copyright information in PMC

References

    1. Fitzpatrick R., Davey C., Buxton M.J., Jones D.R. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998;2(i–iv):1–74. - PubMed
    1. Griffin D., Wall P., Realpe A., et al. UK FASHIoN: feasibility study of a randomised controlled trial of arthroscopic surgery for hip impingement compared with best conservative care. Health Technol Assess. 2016;20:1–172. - PMC - PubMed
    1. Bodger K., Ormerod C., Shackcloth D., Harrison M. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut. 2014;63:1092–1102. - PMC - PubMed
    1. Hvid-Jensen F., Pedersen L., Drewes A.M., Sφrensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375–1383. - PubMed
    1. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's Esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–1057. doi: 10.1093/jnci/djr203. - DOI - PMC - PubMed

LinkOut - more resources